Suppr超能文献

采用行星式珠磨法共研磨活性药物普罗布考与三元稳定剂混合物以改善其溶出度和口服吸收。

Improved dissolution and oral absorption by co-grinding active drug probucol and ternary stabilizers mixtures with planetary beads-milling method.

作者信息

Li Fang, Li Linsen, Wang Shaoning, Yang Yan, Li Jia, Liu Dongchun, Zhang Sijie, Wang Siling, Xu Hui

机构信息

School of Pharmacy, Shenyang Pharmaceutical University, Benxi 117004, China.

Shenyang Medical College, Shenyang 110031, China.

出版信息

Asian J Pharm Sci. 2019 Nov;14(6):649-657. doi: 10.1016/j.ajps.2018.12.001. Epub 2018 Dec 12.

Abstract

The objective of this work is to construct a nanosuspension drug delivery system of probucol, a BCS II drug, in order to improve its dissolution and oral bioavailability. The wet milling procedure using planetary beads-milling equipment was utilized to grind the raw probucol to ultrafine nanoparticle/nanocrystal aqueous suspension that was further solidified by freeze-drying process. Cellulose derivatives of different substitution groups and molecular weights, including HPMC, HPC, and MC, were evaluated as the primary stabilizer of probucol nanosuspension. Ternary stabilizers system composed of a primary stabilizer (cellulose derivative, HPC), a nonionic surfactant (Pluronic® F68), and an anionic surfactant (SDS) was employed to obtain probucol nanosuspension of finer particle size and enhanced dissolution in aqueous media. The probucol nanosuspension with good physical stability showed no obvious change of particle size even after storing over 7 d at 4 °C or 25 °C. The solidified probucol nanosuspension with trehalose as the cryoprotectant showed the highest dissolution rate (> 60% at 2 h) compared to other cryoprotectant. The pharmacokinetic evaluation indicated about 15-folds higher value of the probucol nanosuspension compared to that of coarse probucol suspension after oral administration to rats. The probucol nanosuspension prepared by wet-milling and ternary stabilizers system may find wide applications for improving the dissolution and oral absorption of water-insoluble drugs.

摘要

本研究旨在构建普罗布考(一种BCS II类药物)的纳米混悬液给药系统,以提高其溶出度和口服生物利用度。采用行星式珠磨设备的湿磨工艺将原料药普罗布考研磨成超细纳米颗粒/纳米晶体水混悬液,并通过冷冻干燥工艺进一步固化。评估了不同取代基团和分子量的纤维素衍生物,包括羟丙甲纤维素(HPMC)、羟丙基纤维素(HPC)和甲基纤维素(MC),作为普罗布考纳米混悬液的主要稳定剂。采用由主要稳定剂(纤维素衍生物,HPC)、非离子表面活性剂(普朗尼克® F68)和阴离子表面活性剂(十二烷基硫酸钠,SDS)组成的三元稳定剂体系,以获得粒径更细且在水性介质中溶出度更高的普罗布考纳米混悬液。具有良好物理稳定性的普罗布考纳米混悬液即使在4℃或25℃下储存超过7天,粒径也无明显变化。以海藻糖作为冷冻保护剂的固化普罗布考纳米混悬液与其他冷冻保护剂相比,溶出率最高(2小时时>60%)。药代动力学评估表明,大鼠口服给药后,普罗布考纳米混悬液的值比粗普罗布考混悬液高约15倍。通过湿磨和三元稳定剂体系制备的普罗布考纳米混悬液在改善水不溶性药物的溶出度和口服吸收方面可能具有广泛的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/7032176/dd4efc5baad3/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验